474 Intratumoral CTLA-4-targeting INTASYL™ self-delivering RNAi enhances tumor control in combination with systemic anti-PD-1 antibody therapy in vivo suggesting a strategy to mitigate irSAEs

• Melissa Maxwell,
• Dingxue Yan,
• James Cardia,
• Benjamin Cuiffo,
• Brianna Rivest,
• Andrew Boone

Affiliations

Melissa Maxwell

2Phio Pharmaceuticals, Marlborough, MA, USA

Dingxue Yan

2Phio Pharmaceuticals, Marlborough, MA, USA

James Cardia

Phio Pharmaceuticals, Marlborough, MA, USA

Benjamin Cuiffo

Phio Pharmaceuticals, Marlborough, MA, USA, n/a

Brianna Rivest

Phio Pharmaceuticals, Marlborough, MA, USA

Andrew Boone

Phio Pharmaceuticals Corp., Marlborough, MA, USA